You might be interested in…ADHD

Attention-deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition, affecting both children and adults. Individuals with ADHD face various challenges and have an increased risk of premature death, particularly due to unnatural causes.

A recent observational cohort study in Sweden investigated the impact of ADHD pharmacotherapy on reducing all-cause mortality risk in individuals with ADHD. The study revealed a lower mortality risk in those who initiated treatment, especially for deaths due to unnatural causes.

Global estimates of ADHD prevalence vary significantly, influenced by the study’s methodology. Parenting and family environment play a crucial role in child development and may influence the risk of ADHD.

Research suggests that parenting quality, maltreatment, parental relationship status, and child media exposure can directly impact ADHD outcomes. Strategies to support parents and improve parenting challenges may contribute to better long-term developmental health.

Concerns about the safety of current ADHD medications highlight the need for more effective and safer treatment options for adults with ADHD. Ongoing research aims to develop new treatments that are both efficacious and well-tolerated.

Metabolomics offers a promising approach to identifying biomarkers for precise ADHD diagnosis and targeted interventions. While no simple blood test is currently available, metabolic signatures related to amino acid metabolism and neurotransmitter dysregulation show potential as future diagnostic markers.

References:

1. Li L et al. ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA 2024 Mar 12;331(10):850–860. doi: 10.1001/jama.2024.0851
2. Popit S et al. Prevalence of attention-deficit hyperactivity disorder (ADHD): systematic review and meta-analysis. European Psychiatry 2024, 67(1), e68, 1–23 https://doi.org/10.1192/j.eurpsy.2024.1786
3. Claussen A et al. All in the Family? A Systematic Review and Meta‑analysis of Parenting and Family Environment as Risk Factors for Attention‑Deficit/Hyperactivity Disorder (ADHD) in Children. Prevention Science 2022 https://doi.org/10.1007/s11121-022-01358-4
4. Veronesi G et al. Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults. Neurosci Biobehav Rev 2024 Aug:163:105774. doi: 10.1016/j.neubiorev.2024.105774 Epub 2024 Jun 22.
5. Predescu E et al. Metabolomic Markers in Attention-Deficit/Hyperactivity Disorder (ADHD) among Children and Adolescents—A Systematic Review. Int. J. Mol. Sci. 2024, 25, 4385. https://doi.org/10.3390/ijms25084385